FindTrial
Sign In

TNX-1500

DRUG2 trials

Sponsors

Ayman Al Jurdi, MD, Tonix Pharmaceuticals, Inc.

Conditions

ImmunosuppressionImmunosuppression After Kidney TransplantationKidney TransplantKidney Transplant Failure and RejectionPhase 1 First-in-human Study Involving Healthy Subjects

Phase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
CompletedNCT07473752
Tonix Pharmaceuticals, Inc.Phase 1 First-in-human Study Involving Healthy Subjects
Start: 2023-07-18End: 2024-02-22Updated: 2026-03-16

Phase 2

(TNX-1500) in Kidney Transplant Recipients
Not yet recruitingNCT07204080
Ayman Al Jurdi, MDImmunosuppression, Immunosuppression After Kidney Transplantation, Kidney Transplant +1
Start: 2026-07-01End: 2029-06-30Target: 5Updated: 2026-02-25